CN113646425B - 一种异质性干细胞群、其制备方法及用途 - Google Patents
一种异质性干细胞群、其制备方法及用途 Download PDFInfo
- Publication number
- CN113646425B CN113646425B CN202080024608.1A CN202080024608A CN113646425B CN 113646425 B CN113646425 B CN 113646425B CN 202080024608 A CN202080024608 A CN 202080024608A CN 113646425 B CN113646425 B CN 113646425B
- Authority
- CN
- China
- Prior art keywords
- heterogeneous
- stem cell
- cell population
- cells
- stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 175
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims abstract description 48
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims abstract description 48
- 102100039956 Geminin Human genes 0.000 claims abstract description 9
- 101000886596 Homo sapiens Geminin Proteins 0.000 claims abstract description 9
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims abstract description 9
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims abstract description 9
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims abstract description 9
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims abstract description 9
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 113
- 230000014509 gene expression Effects 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 38
- 238000000338 in vitro Methods 0.000 claims description 25
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 21
- 230000004069 differentiation Effects 0.000 claims description 19
- 230000008499 blood brain barrier function Effects 0.000 claims description 15
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 13
- 230000006870 function Effects 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 13
- 230000006044 T cell activation Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 7
- 229940116977 epidermal growth factor Drugs 0.000 claims description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000003307 reticuloendothelial effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 33
- 150000003384 small molecules Chemical class 0.000 description 22
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 210000003668 pericyte Anatomy 0.000 description 13
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 12
- 206010067125 Liver injury Diseases 0.000 description 11
- 101100078001 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSC2 gene Proteins 0.000 description 11
- 231100000439 acute liver injury Toxicity 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 9
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000001130 astrocyte Anatomy 0.000 description 9
- 238000003501 co-culture Methods 0.000 description 9
- 238000011977 dual antiplatelet therapy Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 101150103623 NOTCH3 gene Proteins 0.000 description 6
- 102000001760 Notch3 Receptor Human genes 0.000 description 6
- 108010029756 Notch3 Receptor Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 102100036537 von Willebrand factor Human genes 0.000 description 6
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 101800001026 Irisin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 5
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000004668 G2/M phase Effects 0.000 description 4
- 238000012404 In vitro experiment Methods 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 101150117600 msc1 gene Proteins 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 101100228809 Mus musculus Gmnn gene Proteins 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 230000009815 adipogenic differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 210000003195 fascia Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102100033347 AP-2 complex subunit beta Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102100036873 Cyclin-I Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100034523 Histone H4 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000732341 Homo sapiens AP-2 complex subunit beta Proteins 0.000 description 2
- 101000907941 Homo sapiens Centromere protein F Proteins 0.000 description 2
- 101000713124 Homo sapiens Cyclin-I Proteins 0.000 description 2
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 2
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001089120 Homo sapiens Proteasome subunit beta type-3 Proteins 0.000 description 2
- 101000598025 Homo sapiens Talin-1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 102100036977 Talin-1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000007418 data mining Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- -1 fn1 Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008975 immunomodulatory function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 229940028444 muse Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 description 1
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 101150037241 CTNNB1 gene Proteins 0.000 description 1
- 101150061453 Cebpa gene Proteins 0.000 description 1
- 101150004620 Cebpb gene Proteins 0.000 description 1
- 101150023376 Cebpd gene Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 102100039950 Eukaryotic initiation factor 4A-I Human genes 0.000 description 1
- 101150118938 FLK gene Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101001023028 Gallus gallus Myogenin Proteins 0.000 description 1
- 101150019946 Gsk3b gene Proteins 0.000 description 1
- 101150092640 HES1 gene Proteins 0.000 description 1
- 101150097704 HHEX gene Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000905746 Homo sapiens Cyclic AMP-dependent transcription factor ATF-5 Proteins 0.000 description 1
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 description 1
- 101001136954 Homo sapiens Proteasome subunit beta type-7 Proteins 0.000 description 1
- 101000750285 Homo sapiens Tubulinyl-Tyr carboxypeptidase 1 Proteins 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 206010051792 Infusion related reaction Diseases 0.000 description 1
- 101150078927 KRT18 gene Proteins 0.000 description 1
- 101150043871 MAPK7 gene Proteins 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010063605 Netrins Proteins 0.000 description 1
- 102000010803 Netrins Human genes 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100033755 Proteasome subunit beta type-3 Human genes 0.000 description 1
- 102100035763 Proteasome subunit beta type-7 Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 101100173553 Rattus norvegicus Fer gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101150059272 TBX6 gene Proteins 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 101150082530 TJP1 gene Proteins 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100021163 Tubulinyl-Tyr carboxypeptidase 1 Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 101100326560 Xenopus laevis cdh2-a gene Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 101150097574 gsk gene Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 101150069487 p65 gene Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/03—Coculture with; Conditioned medium produced by non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种异质性干细胞群、其制备方法及用途。具体地,一种异质性干细胞群,其特征在于所述异质性干细胞群中的干细胞表达干性基因MYC、KLF4、GMNN、SOX2和NANOG,并且在所述异质性干细胞群中,表达CD146的干细胞的比率为1%‑50%。
Description
技术领域
本发明涉及一种新的异质性干细胞群,其特征在于成体组织内找到的由胚胎发育后存留的干细胞群体,其表达全能基因c-Myc、Gmnn和Klf4,并且在该混合的异质性干细胞群中,CD146的表达率为1-100%。本发明还涉及所述异质性干细胞群的制备方法及其用途。
背景技术
间充质干细胞(MSC),或者可以定义为多能间充质基质细胞,是异质细胞群(Uccelli等,2008)。MSC的发现通常归功于A.J.的工作。20世纪60年代后期的弗里登斯坦及其同事观察到在塑料培养皿中培养人骨髓(BM)细胞悬浮液导致造血对应物逐渐丧失,有利于增殖粘附的成纤维细胞样细胞集落,能够分化成脂肪细胞、体外(Friedenstein等,1968)、体内(Friedenstein等,1974)、软骨细胞和骨细胞。
首字母缩略词“MSC”在A.I.的工作后开始流行。Caplan等人在1991年提交的文章中提出在成人BM中,干细胞群可以分化成源自中胚层的不同组织的谱(Caplan,1991)。他们将这些细胞称为“间充质干细胞”。后来,Pittenger明确证明了MSC的多向分化能力(Pittenger等,1999)。从这些开创性的研究结果来看,培养扩增的MSC成为许多研究的对象,甚至对这些细胞的确切表征还有待阐明,并且在不同的实验室中没有应用标准化方案。
因此,报告的数据有时是有争议的,并且MSC生物学的许多方面仍然不清楚,这是因为分离程序的多样性、培养方法和组织来源的选择。为了更好地阐明围绕MSC的争议,我们提出了间充质干细胞系统的概念,该系统由来自胚胎发育的不同阶段的所有MSC组成,从胚胎后的后代细胞干细胞到祖细胞。MSC系统的顶部是胚胎样干细胞,即使在胎儿形成后仍留在许多组织中,我们将它们定义为胚胎后多能干细胞(PSC)。
我们鉴定了来自多种人胎儿和成人组织的PSC,并证明这些细胞可以产生内皮细胞、肝上皮细胞、神经细胞、造血细胞、成脂细胞和成骨细胞系。PSC现已被其他团体证实。2010年,Kuroda Y等人在单细胞水平证明成体间充质干细胞(MSC)含有一种独特类型的干细胞,能够产生具有所有三个胚层特征的细胞。这些细胞被称为多谱系分化胁迫耐受(Muse)细胞。从脂肪组织中分离出高度纯化的Muse细胞群,并报道其自发分化为间充质、内胚层和外胚层细胞谱系。
所有这些研究都表明成人组织中存在PSC。我们假设MSC系统中的其他细胞如周细胞和一般MSC是PSC的衍生物。PSC的定义是从干细胞分化的角度出发的。通过多年对这种细胞类型的研究,我们强烈提倡干细胞功能定义的思想。在这里,我们将PSC定义为培养活化的胚后亚多能干细胞(CAPPSC),其具有三个重要的生物学特征:干细胞特性包括多能性和自我更新,低免疫原性和免疫调节功能,微环境和组织平衡。
发明内容
本发明人的研究发现,本发明人提供的新干细胞群与以前报道的MSC不同,其是一组干性更强混合的异质性的干细胞群体;其处于具有表观遗传多能性的常染色质状态,并表达多潜能标记物MYC、KLF4和GMNN。与胚层规范相关的大多数基因由H3K4me3修饰或由H3K4me3和H3K27me3共修饰。通过单细胞RNA-seq解析新干细胞向功能性肝脏细胞分化的过程,也发现在分化的很早阶段,三胚层早期分化相关基因都先后上调表达,当细胞定向肝脏谱系分化后,其它胚层分化相关基因下调表达。
本研究中,单细胞数据分析显示,我们体外分离培养获得的新干细胞群体,表达全能基因c-Myc、Gmnn和Klf4,表达三胚层早期发育相关基因,如外胚层的Nes和Hes1、中内胚层的Pdgfra和Gsc,限定性内胚层的Hhex和Sox17,内胚层器官肝脏发育关键基因ATF5、Tle3、Hnf4a和Krt18的表达较高,中胚层Mesp2、Gata4、Hand1和Tbx6表达很弱,但成骨分化相关基因Wnt5a、Runx2、TAZ明显表达,成脂分化相关的上游调控基因Cebpb、Cebpd、Gsk3a、Gsk3b显著表达,Mapk7中等表达,成脂分化关键转录因子Pparg和Cebpa低或不表达。
有趣的是,我们发现新干细胞中,上皮——间质转换相关关键基因Tjp1、Ctnnb1、Cdh2、Fn1、Vim、Zeb1和Twist1均明显高表达,表明新干细胞处于上皮——间质转换的中间阶段,可以随着不同微环境信号刺激,发生快速的功能转换。
在本发明的一个方面中,提供了一种异质性干细胞群,其特征在于所述异质性干细胞群中的干细胞表达干性基因MYC、KLF4、GMNN、SOX2和NANOG,并且在所述异质性干细胞群中,表达CD146的干细胞的比率为1-100%,优选地,表达CD146的干细胞的比率为1-50%。
进一步地,根据本发明提供的异质性干细胞群,在用含有50%-99%DMEM/F12、0.1-30ng/ml表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中传代所述异质性干细胞群1代、2代、3代、4代、5代、6代、7代、8代、9代、10代或10代以上后,表达CD146的干细胞的比率为1-99%,优选地,表达CD146的干细胞的比率为1-50%。
另一方面,根据本发明提供的异质性干细胞群,在用含有FBS的培养基传代所述异质性干细胞群1代、2代、3代、4代、5代、6代、7代、8代、9代、10代或10代以上后,表达CD146的干细胞的比率为50-100%,优选地,表达CD146的干细胞的比率为55-100%。
进一步地,根据本发明提供的异质性干细胞群,其中表达CD146+弱阳性(其中,表达CD146的干细胞的比率为1-50%,不包括50%为CD146+弱阳性)的干细胞中的干性基因MYC、KLF4、GMNN、SOX2和NANOG的表达水平显著高于表达CD146+++强阳性(其中,表达CD146的干细胞的比率为50-100%为CD146+++强阳性)的干细胞。一种体外诱导根据本发明提供的异质性干细胞群分化成网状血管内皮细胞的方法,所述方法包括在含有50%-99%DMEM/F12、0.1-30ng/ml表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中诱导本发明提供的异质性干细胞群分化成网状血管内皮细胞。
一种体外促进T细胞活化的方法,所述方法包括将根据本发明提供的异质性干细胞群与分离的PBMC在含有LPS的培养基中共培养的步骤。
一种体外抑制T细胞活化的方法,所述方法包括将根据本发明提供的异质性干细胞群与分离的PBMC在含有PolyIC或IFN-γ+TNF-α(I+T)的培养基中共培养的步骤。
根据本发明提供的异质性干细胞群在制备用于修复组织损伤的药物中的用途,优选地,所述组织损伤为肝细胞损伤。
根据本发明提供的异质性干细胞群在制备用于治疗cGVHD的药物中的用途。
一种制备本发明提供的异质性干细胞群的方法,所述方法包括以下步骤:
(1)获得干细胞群;
(2)在含有50%-99%DMEM/F12、0.1-30ng/ml表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中培养步骤1)获得的干细胞群。
另一方面,本发明涉及根据本发明的异质性干细胞群在制备用于构建血脑屏障的试剂中的用途。
另一方面,本发明涉及根据本发明的异质性干细胞群在制备用于诱导分化米色脂肪细胞的试剂中的用途。
另一方面,本发明人发现一个小分子可将新干细胞群体诱导成抑炎型干细胞群体,新干细胞群体在小分子CZ的诱导下可分化成为抑炎型的MSC2,结合体外实验的结果,我们以单细胞测序进一步研究新干细胞群体转化成为抑炎型的MSC2,新的细胞群体经过CZ处理以后,细胞进入了类似于MSC2的抑炎功能活化状态,将用于用于自身免疫性疾病的临床治疗。
因而,本发明进一步提供了一种体外诱导本发明的异质性干细胞群成抑炎型干细胞群体的方法,所述方法包括使本发明的异质性干细胞群与小分子CZ接触。
另一方面,本发明提供了根据以上方法得的抑炎型干细胞群体在制备用于治疗自身免疫性疾病的药物中的用途。
附图说明
图1A表示通过本发明的间充质干细胞培养方法(MSC-AB)与现有技术中的间充质干细胞培养方法(MSC-FBS)获得的异质性干细胞群中MYC、KLF4、GMNN、SOX2和NANOG基因的表达水平;
图1B表示通过本发明的间充质干细胞培养方法(MSC-AB)与现有技术中的间充质干细胞培养方法(MSC-FBS)连续培养获得的间充质干细胞10代中表达CD146的细胞百分比;
图2表示通过本发明的方法获得的异质性干细胞群中,CD146+++强阳性细胞与CD146+弱阳性细胞中CD146、MYC、KLF4、GMNN、SOX2和NANOG基因的表达水平;
图3A表示本发明的培养体系(AB)和现有技术中的培养体系(FBS)培养的异质性干细胞群在诱导血管内皮细胞中的结果图;
图3B表示本发明的培养体系(AB)和现有技术中的培养体系(FBS)培养的异质性干细胞群中血管生成相关基因的相对表达;
图3C表示本发明的方法获得的异质性干细胞群中,CD146+++强阳性细胞与CD146+弱阳性细胞中血管生成相关基因的相对表达;
图4A和图4B表明与对照组人胚肺成纤维细胞(MRC-5)相比,本发明的异质性干细胞能够显著增加T细胞的活化比例;
图4C表明T细胞与本发明方法获得的异质性干细胞群共培养以后CD28表达上调;
图4D表示用磁珠分选方法分选的CD28+、CD28-和未分选群分别与本发明的异质性干细胞群共培养后,CD28的表达;
图4E表示用磁珠分选方法分选的CD28+、CD28-和未分选群分别与本发明的异质性干细胞群共培养后,用CD单抗体激活的T细胞活化;
图4F和图4G表明用LPS诱导本发明的异质性干细胞群后转变为促炎亚型,能够在体外促进T细胞活化;而用PolyIC或IFN-γ+TNF-α(I+T)诱导本发明的异质性干细胞群转变为抑炎亚型,能够抑制T细胞活化;
图4H和图4I表明在大鼠急性肾损伤模型的体内实验中,给予大鼠促炎亚型的异质性干细胞群输注,将会显著增加尿肌酐水平;
图5-1A至5-1C表明利用单细胞测序的方法,经过小分子CZ处理后,MSC的细胞聚类有明显的改变;
图5-1D表明细胞周期相关的基因在细胞群中的表达;
图5-1E表明细胞周期蛋白基因CCNI、组蛋白基因HIST1H4C、着丝粒蛋白基因CENPF、DNA拓扑异构酶基因TOP2A和细胞骨架蛋白基因TLN1都在细胞群中的表达;
图5-1F表明小分子CZ处理后的MSC在细胞周期中更多地处于G2/M期,而G0/G1期细胞所占比例则有所减少;
图5-2A表明对单细胞测序数据进行分析,与天然免疫相关的基因表达;
图5-2B表明转运蛋白基因AP2B1、整合素β1基因ITGB1、EIF4A1、PSMB3和PSMB7基因的表达;
图5-2C表明PBMC与经过小分子CZ处理后的MSC共培养后活化率更低;
图5-2D表明PBMC与经过小分子CZ处理后的MSC共培养后增殖更慢;
图5-3表示不同方式处理的MSC治疗大鼠肾脏损伤后尿肌酐水平;
图6A表示C57BL/6小鼠腹腔注射CCl4诱导ALI后,ALI小鼠注射CD146+弱阳性干细胞、CD146+++强阳性干细胞或PBS后第1、4或7天的炎性细胞浸润;
图6B表示C57BL/6小鼠腹腔注射CCl4诱导ALI后,ALI小鼠注射CD146+弱阳性干细胞、CD146+++强阳性干细胞或PBS后第1、4或7天的ALT水平;
图6C表示C57BL/6小鼠腹腔注射CCl4诱导ALI后,ALI小鼠注射CD146+弱阳性干细胞、CD146+++强阳性干细胞或PBS后第1、4或7天的AST水平;
图6D表示小鼠的存活百分比;
图7A至7D表示本发明的异质性干细胞群治疗cGVHD的实验结果;
图7A表示皮肤总体疗效评分;
图7B表示关节P-ROM评分;
图7C表示随访期1年内主要疗效指标有效性分析(FAS);其中,总体疗效评分的评分依据:皮肤评分、关节筋膜评分和总体等级评分中任意一个评价有效即为总体疗效有效;在治疗后1、2、6和12个月,试验组的部分有效以上例数均大于对照组,差异有统计学意义;试验组总体疗效评分明显优于对照组;
图7D表示随访期1年内其他主要疗效指标有效性分析(FAS);其中,总体疗效评分在治疗后1、2、6和12个月,试验组的部分有效以上例数均大于对照组,差异有统计学意义;试验组总体等级评分明显优于对照组;
图7E表示本发明的异质性干细胞群治疗cGVHD的实验流程图;
图8A表示利用Transwell体外培养血脑屏障的模型示意图。脑微血管内皮细胞培养在上侧,其下部为周细胞,而星形胶质细胞培养在Transwell底部;
图8B表示脑微血管周细胞、内皮细胞及星形胶质细胞免疫荧光染色鉴定。周细胞α-SMA和NG2表达阳性,而vWF和GFAP表达阴性;内皮细胞vWF表达阳性;星形胶质细胞GFAP表达阳性;
图8C和图8D分别表示正常及IL-1β作用下notch3在三细胞中的表达及在IL-1β作用下MMP-9在三细胞中的表达;
图8E表示在IL-1β与DAPT和PDTC分别作用下,notch3、MMP-9、TIMP-1及NF-κB在周细胞中的表达变化;其中,表达变化是相对于对照的倍数变化;
图8F表示明胶酶谱分析对照组和不同处理组(IL-1β、IL-1β+DAPT、IL-1β+PDTC)MMP-9和MMP-2活性变化;
图8G和图8H表示利用Na-F来检测对照组和不同处理组(IL-1β、IL-1β+DAPT、IL-1β+PDTC)BBB通透性的变化。
图9表示IRISIN诱导亚多能干细胞分化为米色脂肪细胞,实时荧光定量和蛋白质印迹检测蛋白UCP1表达(P<0.05)。
具体实施方式
实施例1干细胞群分离和体外扩增培养的方法
本发明的方法包括获得分离的人体组织,包括但不限于:外周血、骨髓、羊膜、脂肪组织、胎盘、脐带、肌肉、皮肤。用胶原酶消化,经梯度离心、过滤,随后在体外培养体系中进行扩增培养多至10代。由该方法分离、培养获得的新干细胞群体具有c-Myc、Gmnn和Klf4及CD146+弱阳性;所述体外培养体系含有50%-99%DMEM/F12、0.1-30ng/ml表皮生长因子和0.1-2%B27、0.1-10%FBS。
具体培养步骤:
1)从胎盘、脐带、肌肉、皮肤中分离提取脂肪的MSC;
2)将获得的脂肪组织分装至离心管中,加入相应体积PBS混匀后800rpm离心3min,重复清洗2次,之后每管加入相应体积0.2%胶原酶37度摇床消化30min;
3)加入PBS终止消化,100微米筛网过滤后1500rpm离心10min,弃去脂肪及上清后获得细胞沉淀之后继续加入PBS清洗细胞2次,1500rpm离心8min,根据脂肪体积每20ml放入一个T75的方式种细胞;
4)传代:观察细胞形态及密度后倒掉旧培养基,用PBS清洗细胞2遍后加入10ml 1x胰酶消化半分钟左右,用几滴血清终止消化,1200rpm离心5min,弃去上清用相应体积培养基重悬细胞种于培养皿中培养。
通过本发明人建立的异质性干细胞群的培养方法,本发明人发现使用我们实验室的培养体系,与普通的异质性干细胞群培养体系(FBS体系)培养的干细胞群相比,在体外高表达干细胞干性相关基因MYC、KLF4、GMNN、SOX2和NANOG(参见图1A)。换用FBS培养体系培养的异质性干细胞群中CD146阳性率明显升高,在7代后达到90%以上,出现类似异质性干细胞群的表型。而使用我们的培养体系培养的异质性干细胞群中,CD146的阳性率保持在50%弱阳性(图1B)。
单克隆抗体检测细胞表型:
收集细胞,计数后以相应浓度重悬细胞,之后在细胞中加入需要检测的相应抗体,根据使用量计算加入,充分混匀后4度孵育30min,之后加入PBS洗涤细胞2次,1000rpm离心5min弃去上清,再加入相应体积PBS重悬细胞,然后上机检测。
实施例2通过本发明的方法获得的异质性干细胞群的分选
接下来我们通过磁珠分选的方法,将我们的培养体系培养的新干细胞中CD146+++(细胞表面标志阳性率表达50%至100%)和CD146+(细胞表面标志阳性率表达1%至50%,不包括50%)细胞群体分选出来进行比较。
具体的分选步骤如下详述:
使用Vario-MACS系统,CD146+正向选择免疫磁珠分选脐带来源间充质干细胞:
(1)收集细胞沉淀,弃上清。
(2)取缓冲液(含D-Hanks、0.5%BSA、2mMolEDTA)重悬细胞沉淀,按每60ul缓冲液107个细胞比例,向细胞悬液中分别加入FcR和CD146+磁珠,均按20ul每107个细胞比例充分吹打混匀,置于4度冰箱,孵育15min。
(3)按照每1ml缓冲液洗涤107个细胞的比例洗涤细胞。收集沉淀。
(4)按照107个细胞/500ul缓冲液的比例重悬细胞。
(5)把LP分选柱放入Vario-MACS系统的磁性区域,加入3ml缓冲液冲洗分选柱3次。待缓冲液完全流出分选柱后,加入细胞悬液。
使用适当量的缓冲液冲洗柱子,待所有液体全部流出分选柱后,将LP分离柱移出MACS系统的磁场,置于收集管上,加入5ml缓冲液,插入活塞快速冲出细胞,获得被CD146+磁珠标记的CD146+++强阳性细胞亚群。我们发现,CD146+弱阳性细胞中上述干性基因的表达水平明显高于CD146+++强阳性细胞(参见图2)。这些结果提示,本发明的方法获得的异质性干细胞群中,CD146+++强阳性细胞的干性低于CD146+弱阳性细胞,在分化谱系上处于CD146+弱阳性细胞下游的干细胞亚群。而在我们的培养体系中培养的异质性干细胞群能够在体外传代中维持高比例CD146+弱阳性细胞,我们将我们的体系称为异质性干细胞群的干性维持体系。
实施例3体外成血管内皮诱导实验
在本实验中,实验步骤如下详述:
1)提前预冷融化matrigol(BD,低生长因子,354230),体积小可提前一小时融化,若体积大需过夜,96孔板(也可在冰冻板背面直接操作)。
2)垂直加入凝胶,每孔40-55ul,注意不要有气泡,先在常温下平衡10分钟再放入37℃静置半小时。
3)在凝胶等待中准备细胞。(也可铺好胶后备用,一周内用完)
4)加入细胞悬液,每孔150ul。
本发明的干细胞干性维持体系培养的异质性干细胞群能够顺利诱导出连接成网状的血管内皮,而现有技术中的MSC培养体系的细胞则不能(参见图3A)。进一步检测血管生成相关基因Ang-1、VASH1、FLK、VEGF、bFGF,显示本发明的干性维持体系培养的异质性干细胞群在诱导过程中高表达成血管相关基因。对分选后的CD146+++强阳性和CD146+弱阳性细胞的比较也得到了类似的结果(参见图3B和图3C)。
如上述结果所示,本发明的培养体系(AB)获得的异质性干细胞群的干性更强,成血管内皮能力更强。
实施例4本发明的异质性干细胞群具有较强的免疫调节能力
在本实验中,实验方法和步骤如下详述:
(1)将干细胞在AB液培养体系中传代至3-5代。
(2)在体外与静息的外周血单个核细胞(PBMC)共培养(1640+10%FBS)7天后,撤除干细胞,并对T细胞进行CD3抗体活化72h。
(3)与对照组人胚肺成纤维细胞(MRC-5)共培养相比,我们的干细胞共培养组能够显著增加T细胞CD28的表达和T细胞的活化比例。
已经报道了MSC具有较强的免疫调节作用,已有许多实验证明MSC能够在体外抑制T细胞的活化和增殖。本发明的干性维持体系培养的异质性干细胞群具有很强的免疫调节作用。
首先,将本发明的方法获得的异质性干细胞群在体外与静息的PBMC共培养7天后,撤除干细胞,并对T细胞进行CD3/CD28抗体共刺激活化。我们发现,与对照组人胚肺成纤维细胞(MRC-5)相比,本发明的异质性干细胞能够显著增加T细胞的活化比例(参见图4A和4B),而普通MSC通常是抑制T细胞活化的。
结果提示,在本发明的异质性干细胞群与T细胞共培养的过程中,该干细胞群可能增强T细胞的活化潜能。为了证明这种可能,我们进一步检测了T细胞在与本发明的异质性干细胞群共培养前后共刺激活化途径CD3和CD28基因的表达,发现跟我们预期的一样,CD28基因在共培养后有显著的上调(参见图4C)。
为了进一步明确上调的CD28分子的来源,我们用磁珠分选的方法将CD28+/-的T细胞分离开来,分别与本发明的异质性干细胞群共培养,与对照组相比,我们发现CD28-的T细胞群和未分选的T细胞群中CD28分子的上调显著(参见图4D)。对分选后再共培养的T细胞群进行CD单抗体激活(去除CD28抗体的影响),我们发现与本发明的异质性干细胞群共培后各群T细胞的活化率都显著增强(参见图4E)。
此外,本发明的异质性干细胞群也具有与普通MSC相似的免疫可塑性。用LPS诱导本发明的异质性干细胞群后转变为促炎亚型,能够在体外促进T细胞活化;而用PolyIC或IFN-γ+TNF-α(I+T)诱导本发明的异质性干细胞群转变为抑炎亚型,能够抑制T细胞活化(参见图4F和图4G)。
在大鼠急性肾损伤模型的体内实验中,我们发现给予大鼠促炎亚型的异质性干细胞群输注,将会显著增加尿肌酐水平,且病理切片显示肾脏炎性细胞浸润增加,纤维素样坏死加重。而给予大鼠抑炎亚型输注,炎性细胞浸润则大大降低,且系膜细胞溶解和增殖减轻,其中I+T组主要表现为炎性细胞浸润减少,PolyIC组主要表现为细胞增殖减轻(参见图4H和4I)。
结论:本发明的方法获得的新干细胞是一群混合的异质性干细胞群,其能够在本发明人的干性维持培养体系中保持多能性至少达10代。这是一个区分于普通MSC的重要特性,使得本发明的异质性干细胞群能够在较长的窗口期被诱导分化为下游功能细胞,如血管内皮细胞,这种在血管衰老中重要的指示细胞。
CD146(MCAM)是一种细胞黏附分子,通常被用作内皮细胞和周细胞的标记物。最近也有研究显示,CD146是神经神经生长因子(netrin)的受体和血管生成因子受体2(VEGFR2)的共受体。我们的实验结果证实了CD146分子与本发明的异质性干细胞群的干性之间存在着一种紧密的相关性,它是否能成为新干细胞的潜在标记物,需要未来进行进一步的研究。
CD28是T细胞表面的一种免疫共激活分子,出生时几乎所有的T细胞均为CD28+。随着机体在成长和衰老过程中的抗原暴露,T细胞逐渐丢失CD28表型,并失去活化的能力。因此CD28成为一种指示免疫系统衰老的分子。本发明的新干细胞群能够在与PBMC共培后显著提高T细胞群体表达CD28的比例,因此我们认为新干细胞能够增强T细胞的活化潜能和免疫功能,特别是针对年龄在65岁以上的人,他们的T细胞中50-60%的CD8+T细胞和5-10%CD4+T细胞缺乏CD28分子。这个发现使得新干细胞治疗免疫系统衰老成为一种极具希望的细胞治疗方式。
实施例5小分子CZ可将本发明的异质性干细胞群诱导成抑炎型干细胞群体
小分子CZ的产品名称为氯唑沙宗,目录编号:TCZ;CAS号码:95-25-0;其分子式为C7H4ClNO2;分子量为169.57。存储:-80℃的溶剂下保存2年;-20℃的粉剂下3年。
氯唑沙宗是一种中枢作用的肌肉松弛剂,用于治疗肌肉痉挛和由此引起的疼痛或不适。通过抑制反射作用于脊髓。氯唑沙宗目前被用作体外/体内研究的标记物底物,以量化人体中的细胞色素P4502E1(CYP2E)活性。
其物理特性:
沸点:181℃~192℃
熔点:N/A
溶解度:二甲基甲酰胺(DMF),34mg/ml(200.5mM)
二甲基亚砜(DMSO),34mg/ml(200.5mM)
水
该研究目的仅用于诊断或治疗用途。
产品数据表中列出了产品储存和处理的信息Targetmol产品在推荐的储存条件下长期稳定。我们的产品可能在不同的条件下运输,因为许多产品在较高或甚至室温下都能在短期内保持稳定。我们确保产品在保持试剂质量的条件下运输。收到产品后,请按照产品数据表中的存储建议进行操作。
本发明人发现异质性干细胞群体在小分子CZ的诱导下可分化成为抑炎型的MSC2(干细胞群体),结合体外实验的结果,我们以单细胞测序进一步研究本发明的异质性干细胞群体转化成为抑炎型的MSC2,该细胞群体经过CZ处理以后,细胞进入了类似于MSC2的抑炎功能活化状态,将用于自身免疫性疾病的临床治疗。
小分子CZ能够增加MSC的增殖能力
利用单细胞测序的方法,我们发现经过小分子CZ预处理48h后,MSC的细胞聚类有明显的改变(图5-1A)。与细胞周期相关的基因表达显示,经过小分子CZ处理以后的MSC更多地表达S期和G2/M期的基因(图5-1B)。对对照组和小分子CZ处理组进行仔细聚类分析以后,我们发现细胞群2(cluster2)是其中变化最大的细胞群体,细胞群2在CZ处理以后的样本中完全消失,且仅表达G1期和S期的基因,而不表达G2/M期的基因(图5-1A、5-1B、5-1C)。因此接下来我们对细胞群2进行了细胞周期相关基因的仔细分析。我们在细胞群2中发现,与细胞周期相关的基因在细胞群2中的表达高低与其他群体细胞有明显的差异(图5-1D)。其中细胞周期蛋白基因CCNI,组蛋白基因HIST1H4C、着丝粒蛋白基因CENPF、DNA拓扑异构酶基因TOP2A和细胞骨架蛋白基因TLN1都在细胞群2中相对低表达而在其他细胞群体中高表达(图5-1E)。
体外实验也显示,用小分子CZ处理后的MSC在细胞周期中更多地处于G2/M期,而G0/G1期细胞所占比例则有所减少(图5-1F)。
小分子CZ能够增加MSC的免疫调节功能
进一步对单细胞测序数据中的进行分析,我们发现,与天然免疫相关的基因表达中细胞群2和其他群体细胞也有明显不同(图5-2A)。在差异最明显的蛋白中,我们发现,转运蛋白基因AP2B1和整合素β1基因ITGB1在细胞群2中低表达,其中前者可参与TGFβ受体介导的胞吞作用而后者参与IL1β受体介导的IL1β信号通路,且在微生物感染免疫中参与重要作用。而相反的是,参与组成20s蛋白酶复合体的基因PSMB3和PSMB7基因则在细胞群2中高表达,表明细胞群2以外的细胞泛素化的蛋白水解较慢,因此蛋白的功能普遍较强(图5-2B)。
体外实验也表明,PBMC与经过小分子CZ处理后的MSC共培养后活化率更低(图5-2C),增殖更慢(图5-2D)。因此,小分子CZ能够促进MSC的免疫抑制功能。
结论:经过单细胞数据的多方面分析,我们认为,细胞群2细胞是一类较为静息的细胞群体,它们在未经小分子活化的状态下处于功能原始状态。而在经过小分子CZ处理后,新的干细胞群体进入一个功能活化的状态,细胞周期加快,增殖速度加快,且与免疫调节功能相关的基因表达也随之改变。
MSC的免疫抑制功能已经广为人知,目前已成功进入临床治疗自身免疫疾病,如GvHD等。但在治疗过程中有少部分病例出现疗效不如预期甚至效果相反的现象。MSC是一个异质性的细胞群体,我们认为MSC群体中能够有效抑制免疫反应的细胞比例不够,那么在体内的疗效就会大打折扣。
目前已有理论提出MSC分为促炎型的MSC1和抑炎型的MSC2,已知LPS能诱导促炎型的MSC1,IFN-γ+TNF-α、poly(I:C)能够诱导MSC向抑炎型的MSC2转变,但由于经过这样方式处理以后的MSC免疫原性显著增强,不能广泛用于临床治疗,故我们希望找到一种临床级小分子能够增强MSC的免疫抑制功能,或者增加MSC群体中的MSC2的比例,但不会明显改变MSC的免疫原性。
通过大数据挖掘和功能筛选,我们找到了一种代号为CZ的小分子化合物,它是一种FDA批准的临床药物。在大鼠急性肾损伤模型中,我们发现,给予大鼠促炎亚型(LPS处理组)的MSC1输注,将会显著增加尿肌酐水平;而给予大鼠抑炎亚型的MSC2(I+T、poly(I:C)、CZ组)输注,尿肌酐水平明显降低,其中小分子CZ的效果最显著(图5-3)。在病理组织切片中,促炎型MSC1增加了肾脏炎性细胞浸润增加,加重了肾小球纤维素样坏死;而抑炎型MSC2使得炎性细胞浸润大大降低,系膜细胞溶解和增殖减轻。
小分子CZ的筛选过程:
1.大数据挖掘人MSC免疫调节中的关键分子IDO的相互作用蛋白;
2.在获得的蛋白中进行功能筛选,从而得到了能够增强MSC免疫抑制功能的CZ分子。
实施例6本发明的异质性干细胞群与组织损伤修复
本实施例研究了来自本发明异质性干细胞群体在急性肝损伤(ALI)中的不同疗效。
C57BL/6小鼠腹腔注射CCl4诱导ALI,6小时后,ALI小鼠注射5×105CD146+弱阳性干细胞、CD146+++强阳性干细胞或PBS(安慰剂治疗组)。在第1天,对照组中有更多的炎性细胞浸润,并且所有三组均具有轻微的球囊样改变。在第4天,对照组具有广泛的球囊样变化和大量炎性细胞浸润,而在CD 146+++强阳性干细胞移植组中观察到大的坏死病灶和广泛的球状样变化。在第7天,三组恢复正常肝脏组织学(参见图6A),CD 146+++强阳性干细胞移植组具有显着更高水平的ALT(p=0.027)和AST(p=0.012)(参见图6B和图6C)。另外,肝内CD146+++强阳性和CD146+弱阳性干细胞的数量在第4天最高,肝内CD146+++强阳性干细胞的数量低于CD146+弱阳性干细胞。
干细胞(CD 146+弱阳性)治疗组的存活率显着高于安慰剂治疗组(82%对54.5%)(参见图6D)。PSC治疗组血清肝酶丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)的峰值水平显着低于安慰剂治疗组(P<0.01)因此,PSC给药显着减轻CCl4诱导的急性肝损伤。
实施例7本发明的异质性干细胞群治疗cGVHD的疗效
从2012年1月至2015年10月期间,共招募了35名符合条件的患者。患者分为两组,并进行一线免疫抑制治疗。实验组另外接受4剂骨髓内本发明的异质性干细胞群的输注,其中临床试验的流程参见图7E)。
我们的结果表明,本发明的异质性干细胞群的输注分别显着改善了难治性ScGVHD的临床结果,包括皮肤,关节和筋膜,cGVHD症状的总体严重程度和总体反应(P<0.05)(参见图7A-7D)。实验组的总反应率(ORR)在6个月达到峰值82.1%,而对照组的ORR仅为23.1%。没有观察到与MSC输注相关的早期或晚期安全性问题。
从上述数据来看,关节和筋膜似乎对PSC治疗更敏感,6个月时有90%的RR,而只有一半的患者对PSCs治疗有皮肤反应。为了确定皮肤对PSC治疗反应的预后因素,我们比较了皮肤反应者和非皮肤反应者之间的基线人口统计学和临床特征(包括性别,年龄,疾病,供体,cGVHD持续时间,基线NIH皮肤评分,KPS和PSCs剂量)。只有供体类型在皮肤反应者和非反应者之间具有临界显着性差异(P=0.077)。在6个月时,从匹配的同胞供体接受移植的患者的皮肤反应率为72.7%,而接受半相合供体移植的患者的反应率仅为22.2%。
进行流式细胞术以测量基线和1年随访期间两个臂之间的T淋巴细胞亚群。注射PSC后Treg的百分比和Th1/Th2的比例均升高,并且在2次注射PSC后达到峰值,并且在随访期间逐渐下降。在每个评估点处,在两个组之间没有观察到Treg百分比和Th1/Th2比率的差异(P>0.05)。
向28名患者施用总共112个PSC骨髓内输注。所有输注都耐受良好。未观察到急性输注相关反应和PSC输注相关不良事件。在随访期间,登记的患者中共观察到6例死亡。
实施例8本发明的异质性干细胞群在干预血脑屏障药物中的用途
血脑屏障是由脑微血管内皮细胞、周细胞及星形胶质细胞组成。周细胞在血脑屏障中起到很重的作用,同时它也属于中医三焦结构主要功能细胞一新干细胞群体/周细胞群体,三焦器官关联五脏六腑及周身器官组织,通过气血运行、传导感应、互相协调,已到达人体经络功能的调控,三焦器官/间充质组织系统主要负责干细胞多组织增殖分化、组织器官再生修复和功能重建,参与人体免疫监督、应答及复杂免疫网络调控作用等,发挥着脑疾病及神经修复、组织间激素、内分泌调节及组织代谢的系统性调节功能。
影像学表现为脑白质病变,提示血脑屏障有破坏,其中炎症是参与原因之一,小血管病脑损伤的发病机制是局部炎症导致的血脑屏障损伤引起。炎症对血脑屏障的损伤机制尚未完全阐明。
我们应用本发明方法获得的异质性干细胞群,定向诱导分化为脑微血管内皮细胞、周细胞及星形胶质细胞,从而构建了血脑屏障。
诱导分化的方法步骤和血脑屏障的确立如下进行:
我们将白细胞介素1β(IL-1β)加入到Transwell体外血脑屏障模型中,体外培养人脑微血管内皮细胞(HBMVECs)、人脑周细胞(HBPs)和人脑星形胶质细胞(HBAs)。我们用免疫荧光染色鉴定了HBMVECs、HBPs和HBAs,其中HBMVEC用vWF染色,HBP用α-SMA和NG2抗体染色,而vWF和GFAP不染色,HBA用GFAP染色(图8B)。在正常情况下,q-PCR结果提示HBP表达NOTCH3基因,而HBMVEC和HBA不表达NOTCH3(图8C)。HBP、HBMVEC和HBA与IL-β共培养24小时,HBP组观察到NOTCH3基因表达,HBMVEC和HBA组NOTCH3基因并没有表达(图8D)。用IL-1β处理HBP30分钟,然后用DAPT 24小时,q-PCR结果表示在图8E中,从图8E中可见,与对照组相比,IL-1β组NOTCH3基因表达增加,而与IL-1β组相比,IL-1β+DAPT组的NOTCH3基因表达减少。同时,MMP-9基因表达的结果与NOTCH3相似,但三组中TIMP-1基因表达的结果变化不大。HBP经IL-1β处理30分钟后,PDTC处理24小时,q-PCR结果显示,IL-1β组与对照组相比,Notch3基因表达显著增加,但与IL-1β组相比,IL-1β+PDTC组变化不大。同时,与对照组相比,IL-1β组MMP-9基因表达结果显著增加,IL-1β+DAPT组MMP-9基因表达结果与IL-1β组相比显著降低,但三组TIMP-1基因表达结果变化不大。用IL-1β处理HBP 30分钟,DAPT处理24小时,q-PCR结果显示,与对照组相比,IL-1β组的NF-κB p65基因表达显著增加,而与IL-1β组相比,IL-1β+DAPT组的表达显著降低。同时,PDTC处理组NF-κB p65基因表达结果与DAPT处理组相似(参见图8E)。
图8A表明了利用Transwell体外培养血脑屏障的模型示意图。脑微血管内皮细胞培养在上侧,其下部为周细胞,而星形胶质细胞培养在Transwell底部;
图8B表明了脑微血管周细胞、内皮细胞及星形胶质细胞免疫荧光染色鉴定。周细胞α-SMA和NG2表达阳性,而vWF和GFAP表达阴性;内皮细胞vWF表达阳性;星形胶质细胞GFAP表达阳性;
图8C和8D分别表示正常及IL-1β作用下notch3在三细胞中的表达及在IL-1β作用下MMP-9在三细胞中的表达;
图8E表示在IL-1β与DAPT和PDTC分别作用下,notch3、MMP-9、TIMP-1及NF-κB在周细胞中的表达变化;其中,表达变化是相对于对照的倍数变化;
图8F表示明胶酶谱分析对照组和不同处理组(IL-1β、IL-1β+DAPT、IL-1β+PDTC)MMP-9和MMP-2活性变化;
图8G和8H表示利用Na-F来检测对照组和不同处理组(IL-1β、IL-1β+DAPT、IL-1β+PDTC)BBB通透性的变化。
实施例9本发明的异质性干细胞群调节脂肪细胞组织代谢用途
近几年新发现一种激素IRISIN,是锻炼后分泌的一种肌因子,由它的前体-纤连蛋白III结构包含5(Fndc5)剪切释放,其功能涉及在在肌肉、心血管、神经及能量代谢方面。在能量调节过程中,IRISIN在糖代谢中是一个潜在的调节子。本研究中,我们采用本发明的异质性干细胞群作为种子细胞,IRISIN诱导其分化为米色脂肪细胞(参见图9)。
诱导的方法、步骤如下详述:
脂肪组织用含有双抗生素(青霉素、链霉素)的D-Hanks’洗涤2次,800rpm离心3min;将洗涤后的下层液体用移液管吸出,将脂肪组织转至新的50ml离心管内,加入0.2%胶原酶P消化,于37℃恒温培养震荡器震荡30min;加入适量D-Hanks’液将消化后的脂肪组织,100μm细胞滤网过滤,去除未消化的组织,1500rpm离心10min;将上层油脂用移液管吸出后,弃上清,D-Hanks’重悬细胞沉淀,洗涤1次,1500rpm离心10min;弃上清,用12ml含适量双抗生素hAD-MSC工作液重悬2×106细胞接种于T75培养瓶内,于37℃恒温、5%CO2饱和湿度细胞培养箱培养;原代细胞接种48h后,除去上层未贴壁的细胞,继续培养,每隔2-3天全量换液一次;细胞达80%汇合时,可进行传代或冻存保种。
本发明的方法获得的新干细胞群,并非单指分化潜能上的新,而是信号易感性新,能够接受不同类型的信号,转变为不同的亚型,某方面功能增强。比如,不同免疫微环境刺激下,可以转化为促炎型和抑炎型功能亚类。在高浓度FBS培养条件下,转变为CD146+++强阳性亚群,对T细胞调节功能增强,向成骨分化能力增强,向成脂分化能力减弱,基本丧失成血管能力;而在低浓度FBS培养条件下,转变为CD146+弱阳性亚群,表现为免疫能力下降,成脂及成血管能力增强,成骨能力减弱。在寒冷、运动或者应急信号刺激下,新接收来自肌肉分泌的irisin信号,变为易于分化为米色脂肪的前体细胞。
Claims (11)
1.一种异质性干细胞群,其特征在于所述异质性干细胞群中的干细胞表达干性基因MYC、KLF4、GMNN、SOX2和NANOG;其中,
表达CD146+弱阳性的干细胞中的干性基因MYC、KLF4、GMNN、SOX2和NANOG的表达水平显著高于表达CD146+++强阳性的干细胞,其中,所述CD146+弱阳性是指表达CD146的干细胞的比率为1-50%,不包括50%;所述CD146+++强阳性是指表达CD146的干细胞的比率为50-100%;其中,
所述异质性干细胞群在用含有50%-99%DMEM/F12、0.1-30ng/m1表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中传代1代、2代、3代、4代、5代、6代、7代、8代、9代、10代或10代以上后,得到的表达CD146的干细胞的比率为1-50%。
2.一种体外诱导根据权利要求1所述的异质性干细胞群分化成网状血管内皮细胞的方法,所述方法包括在含有50%-99%DMEM/F12、0.1-30ng/m1表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中诱导根据权利要求1所述的异质性干细胞群分化成网状血管内皮细胞。
3.一种体外调节T细胞活化的方法,所述方法包括将根据权利要求1所述的异质性干细胞群与分离的PBMC在含有LPS的培养基中共培养的步骤,从而促进T细胞活化;或者所述方法包括将根据权利要求1所述的异质性干细胞群与分离的PBMC在含有PolyIC或含有IFN-γ和TNF-α的培养基中共培养的步骤,从而抑制T细胞活化。
4.根据权利要求1所述的异质性干细胞群在制备用于修复组织损伤的药物中的用途,其中所述组织损伤为肝细胞损伤。
5.根据权利要求1所述的异质性干细胞群在制备用于治疗cGVHD的药物中的用途,其中所述cGVHD为ScGVHD。
6.一种制备根据权利要求1所述的异质性干细胞群的方法,所述方法包括以下步骤:
1)获得干细胞群;
2)在含有50%-99%DMEM/F12、0.1-30ng/m1表皮生长因子和0.1-2%B27、0.1-10%FBS的培养基中培养步骤1)获得的干细胞群。
7.根据权利要求1所述的异质性干细胞群在用于构建血脑屏障中的用途,所述用途是非治疗目的的。
8.根据权利要求1所述的异质性干细胞群在用于诱导分化为米色脂肪细胞中的用途,所述用途是非治疗目的的。
9.一种体外诱导根据权利要求1所述的异质性干细胞群成抑炎型干细胞群体的方法,所述方法包括使根据权利要求1所述的异质性干细胞群与氯唑沙宗接触,氯唑沙宗的潜在通路是mTOR-AKT-FOXO3-IDO信号通路轴,最终通过促进IDO的转录来达到促进MSC免疫抑制的功能。
10.根据权利要求9的方法获得的抑炎型干细胞群体。
11.根据权利要求9的方法获得的抑炎型干细胞群体在制备用于治疗自身免疫性疾病的药物中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910527634.5A CN112094804B (zh) | 2019-06-18 | 2019-06-18 | 一种异质性干细胞群、其制备方法及用途 |
CN2019105276345 | 2019-06-18 | ||
PCT/CN2020/096750 WO2020253763A1 (zh) | 2019-06-18 | 2020-06-18 | 一种异质性干细胞群、其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113646425A CN113646425A (zh) | 2021-11-12 |
CN113646425B true CN113646425B (zh) | 2024-03-19 |
Family
ID=73748404
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910527634.5A Active CN112094804B (zh) | 2019-06-18 | 2019-06-18 | 一种异质性干细胞群、其制备方法及用途 |
CN202080024608.1A Active CN113646425B (zh) | 2019-06-18 | 2020-06-18 | 一种异质性干细胞群、其制备方法及用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910527634.5A Active CN112094804B (zh) | 2019-06-18 | 2019-06-18 | 一种异质性干细胞群、其制备方法及用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220267734A1 (zh) |
EP (1) | EP3988647A4 (zh) |
CN (2) | CN112094804B (zh) |
AU (1) | AU2020296774A1 (zh) |
CA (1) | CA3143088A1 (zh) |
WO (1) | WO2020253763A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112094804B (zh) * | 2019-06-18 | 2024-05-14 | 中国医学科学院基础医学研究所 | 一种异质性干细胞群、其制备方法及用途 |
CN117327647B (zh) * | 2023-12-01 | 2024-02-27 | 山东第一医科大学(山东省医学科学院) | 一种高纯度Muse细胞的培养方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008132722A1 (en) * | 2007-04-26 | 2008-11-06 | Ramot At Tel-Aviv University Ltd. | Pluripotent autologous stem cells from oral mucosa and methods of use |
CN103261407A (zh) * | 2010-12-22 | 2013-08-21 | 杜兰教育基金委员会 | 用于识别和培养具有高度增殖潜能的多能间充质干细胞的方法 |
CN105101965A (zh) * | 2013-03-15 | 2015-11-25 | 安皮奥制药股份有限公司 | 用于干细胞活动化、归巢、扩增和分化的组合物及其使用方法 |
CN106566810A (zh) * | 2016-10-19 | 2017-04-19 | 广州赛莱拉干细胞科技股份有限公司 | 一种组合物、含有该组合物的诱导制剂及诱导方法 |
CN106801035A (zh) * | 2017-01-24 | 2017-06-06 | 中国医学科学院基础医学研究所 | 一种人脂肪来源间充质干细胞的预处理方法 |
CN112094804A (zh) * | 2019-06-18 | 2020-12-18 | 中国医学科学院基础医学研究所 | 一种异质性干细胞群、其制备方法及用途 |
CN115089611A (zh) * | 2022-06-28 | 2022-09-23 | 北京三有利康细胞科技有限公司 | 一种cd146+或cd146-脐带间充质干细胞亚群在制备防治脓毒症的产品中的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054819A2 (en) * | 2006-11-02 | 2008-05-08 | The General Hospital Corporation | Cardiovascular stem cells, methods for stem cell isolation, and uses thereof |
WO2009007979A2 (en) * | 2007-07-11 | 2009-01-15 | Technion Research & Development Foundation Ltd. | Encapsulated mesenchymal stem cells and uses thereof |
WO2009030092A1 (en) * | 2007-09-05 | 2009-03-12 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof |
CN102048756B (zh) * | 2009-11-04 | 2014-02-19 | 中国医学科学院基础医学研究所 | 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途 |
KR101213055B1 (ko) * | 2010-03-19 | 2012-12-18 | 서울대학교산학협력단 | 피부?유래 전구세포로부터 신경계 및 중배엽계 세포로의 분화 유도 방법 및 이에 이용되는 분화 유도용 조성물 |
CN104487568B (zh) * | 2012-07-11 | 2017-08-15 | 爱姆斯坦生物技术公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
US9994825B2 (en) * | 2013-03-15 | 2018-06-12 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
US10443044B2 (en) * | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
SG11201610795VA (en) * | 2014-08-01 | 2017-02-27 | Purec Co Ltd | Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method |
CN105087467B (zh) * | 2015-08-30 | 2019-03-29 | 中国医学科学院基础医学研究所 | 肾脏足细胞的制备方法及其专用培养基 |
EP3384038A4 (en) * | 2015-11-23 | 2019-12-04 | The Regents of The University of Colorado, A Body Corporate | METHODS AND COMPOSITIONS FOR CELL REPROGRAMMING |
GB201613078D0 (en) * | 2016-07-28 | 2016-09-14 | Univ Oxford Innovation Ltd | Stem cells and cancer |
CN106754658A (zh) * | 2016-12-22 | 2017-05-31 | 江西宜信堂医疗科技有限公司 | 一种培养牙髓干细胞的培养基及其制备方法 |
JP7132908B2 (ja) * | 2017-04-03 | 2022-09-07 | 株式会社カネカ | 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
-
2019
- 2019-06-18 CN CN201910527634.5A patent/CN112094804B/zh active Active
-
2020
- 2020-06-18 AU AU2020296774A patent/AU2020296774A1/en active Pending
- 2020-06-18 CA CA3143088A patent/CA3143088A1/en active Pending
- 2020-06-18 EP EP20827697.2A patent/EP3988647A4/en active Pending
- 2020-06-18 CN CN202080024608.1A patent/CN113646425B/zh active Active
- 2020-06-18 WO PCT/CN2020/096750 patent/WO2020253763A1/zh unknown
- 2020-06-18 US US17/619,108 patent/US20220267734A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008132722A1 (en) * | 2007-04-26 | 2008-11-06 | Ramot At Tel-Aviv University Ltd. | Pluripotent autologous stem cells from oral mucosa and methods of use |
CN103261407A (zh) * | 2010-12-22 | 2013-08-21 | 杜兰教育基金委员会 | 用于识别和培养具有高度增殖潜能的多能间充质干细胞的方法 |
CN105101965A (zh) * | 2013-03-15 | 2015-11-25 | 安皮奥制药股份有限公司 | 用于干细胞活动化、归巢、扩增和分化的组合物及其使用方法 |
CN106566810A (zh) * | 2016-10-19 | 2017-04-19 | 广州赛莱拉干细胞科技股份有限公司 | 一种组合物、含有该组合物的诱导制剂及诱导方法 |
CN106801035A (zh) * | 2017-01-24 | 2017-06-06 | 中国医学科学院基础医学研究所 | 一种人脂肪来源间充质干细胞的预处理方法 |
CN112094804A (zh) * | 2019-06-18 | 2020-12-18 | 中国医学科学院基础医学研究所 | 一种异质性干细胞群、其制备方法及用途 |
CN115089611A (zh) * | 2022-06-28 | 2022-09-23 | 北京三有利康细胞科技有限公司 | 一种cd146+或cd146-脐带间充质干细胞亚群在制备防治脓毒症的产品中的应用 |
Non-Patent Citations (9)
Title |
---|
2%成人AB型血清扩增的骨髓间充质干细胞的分化潜能研究;胡建立等;《中国生物医学工程学报》;第30卷(第06期);第920-924页 * |
3种不同来源CD146阳性间充质干细胞亚群的生物学特性比较;王巧玲等;《基础医学与临床》;20200105(第01期);第49-55页 * |
CD146 Expression Influences Periapical Cyst Mesenchymal Stem Cell Properties;Francesco Paduano等;《Stem Cell Rev Rep》;第12卷(第5期);第599页左栏第2段 * |
CD146+ mesenchymal stem cells display greater therapeutic potential than CD146-cells for treating collagen-induced arthritis in mice;Cheng-Chi Wu等;《Stem Cell Res Ther》;第7卷(第23期);摘要 * |
Generation of Functional Hepatocytes from Human Adipose-Derived MYC+KLE4+GMNN+ Stem Cells Analyzed by Single-Cell RNA-Seq Profiling;Hongling Li等;《Stem Cells Transl Med》;第7卷(第11期);第792-805页 * |
Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats;Jianjun Li等;《J Inflamm (Lond)》;第9卷(第1期);全文 * |
Luchan Deng等.Chlorzoxazone, a small molecule drug,augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation.《Cell Death Dis》.2020,第11卷(第3期),第158篇. * |
TLR3 preconditioning enhances the therapeutic efficafy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway;Y Qiu等;《Mucosal Immunol》;第10卷(第3期);摘要 * |
脂肪来源间充质干细胞体外定向诱导分化血管细胞的研究进展;翟羽佳;仉红刚;;中国生物工程杂志;第30卷(第06期);第134-138页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112094804B (zh) | 2024-05-14 |
EP3988647A1 (en) | 2022-04-27 |
US20220267734A1 (en) | 2022-08-25 |
WO2020253763A1 (zh) | 2020-12-24 |
AU2020296774A1 (en) | 2022-01-20 |
CA3143088A1 (en) | 2020-12-24 |
CN112094804A (zh) | 2020-12-18 |
EP3988647A4 (en) | 2022-08-31 |
CN113646425A (zh) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pereira et al. | Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation | |
De Kock et al. | Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential | |
CN113646425B (zh) | 一种异质性干细胞群、其制备方法及用途 | |
CN111979187B (zh) | 一种抗人间充质干细胞衰老及增强其干性特征的方法 | |
WO2021147923A1 (zh) | 一种囊泡及其应用 | |
WO2009136168A1 (en) | Materials and methods relating to cell based therapies | |
Newman et al. | Transplantation of human umbilical cord blood cells in the repair of CNS diseases | |
Bajek et al. | Human adipose-derived and amniotic fluid-derived stem cells: A preliminary in vitro study comparing myogenic differentiation capability | |
US9700585B2 (en) | Multipotent prenatal stem cells | |
WO2016019332A1 (en) | Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof | |
JP7038782B2 (ja) | 高速かつ効率的にインビトロ増幅ヒト間葉系幹細胞的方法および使用 | |
Bunnell et al. | Common transcriptional gene profile in neurospheres-derived from pATSCs, pBMSCs, and pNSCs | |
CN109749981B (zh) | 人源脂肪干细胞来源的肝细胞样细胞及其制备方法和应用 | |
EP2760995B1 (en) | Renal stem cells isolated from kidney | |
CN105985933A (zh) | 自罹患神经管缺陷胎儿羊水分离人类神经干细胞 | |
CN110592007A (zh) | 一种间充质干细胞及其制备方法和应用 | |
CN114891737B (zh) | 一种多能干细胞来源肾脏间充质干细胞的制备方法及其应用 | |
RU2821926C1 (ru) | Способ получения и ведения мезенхимальных стволовых клеток из костного материала млекопитающих | |
Smolinska et al. | Promising Markers in the Context of Mesenchymal Stem/Stromal Cells Subpopulations with Unique Properties | |
CN110885785B (zh) | 一种分离培养间充质干细胞的方法 | |
Qujeq et al. | Viability and functional recovery of pancreatic islet cells co-cultured with liver, salivary glands and intestine cells | |
Mutlak et al. | Rapid Induction of Mesenchymal Stem Cells to Neural Cells. | |
EP3068872B1 (en) | Non-expanded post-natal multilineage-inducible cells | |
CN118185878A (zh) | 一种microRNA-301a-3p修饰的间充质干细胞及其制备方法与应用 | |
CN115956119A (zh) | 非永生性多能干细胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |